Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

CREDENCE Study Investigators

Research output: Contribution to journal › Article › peer-review

200 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences